HC Wainwright & Co. Maintains Buy on Arcutis Biotherapeutics, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Serge Belanger maintains a 'Buy' rating on Arcutis Biotherapeutics (NASDAQ:ARQT) but has lowered the price target from $22 to $8.
November 06, 2023 | 11:50 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Despite a lowered price target from $22 to $8, HC Wainwright & Co. maintains a 'Buy' rating on Arcutis Biotherapeutics.
The news directly pertains to Arcutis Biotherapeutics. The lowered price target might initially seem negative, but the maintained 'Buy' rating indicates that the analyst still sees potential in the company. This could lead to mixed reactions in the market, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100